pyrazinoic acid has been researched along with Tuberculosis, Multidrug-Resistant in 5 studies
pyrazinoic acid: active metabolite of pyrazinamide; structure
pyrazine-2-carboxylic acid : The parent compound of the class of pyrazinecarboxylic acids, that is pyrazine bearing a single carboxy substituent. The active metabolite of the antitubercular drug pyrazinamide.
Tuberculosis, Multidrug-Resistant: Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Nonlinear mixed-effects modelling using Monolix 2018R1 software was employed to estimate population pharmacokinetic parameters." | 1.51 | Population Pharmacokinetic Modelling of Pyrazinamide and Pyrazinoic Acid in Patients with Multi-Drug Resistant Tuberculosis. ( Mugabo, P; Mulubwa, M, 2019) |
| "Pyrazinamide (PZA) is a critical component of current first-line TB therapy." | 1.48 | Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis. ( Braunstein, M; Durham, PG; Hayden, JD; Hickey, AJ; Lin, FC; Miller, BK; Montgomery, SA; Rank, L; Welch, JT; Young, EF; Zulauf, KE, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, Y | 1 |
| Xu, Y | 1 |
| Guo, C | 1 |
| Xue, X | 1 |
| Lin, D | 1 |
| Lin, K | 1 |
| Montgomery, SA | 1 |
| Young, EF | 2 |
| Durham, PG | 2 |
| Zulauf, KE | 1 |
| Rank, L | 1 |
| Miller, BK | 1 |
| Hayden, JD | 2 |
| Lin, FC | 1 |
| Welch, JT | 2 |
| Hickey, AJ | 2 |
| Braunstein, M | 1 |
| Mugabo, P | 1 |
| Mulubwa, M | 1 |
| Perkowski, E | 1 |
| Malik, S | 1 |
| Zhong, L | 1 |
| Braunstein, MS | 1 |
| Kim, HJ | 1 |
| Kwak, HK | 1 |
| Lee, J | 1 |
| Yun, YJ | 1 |
| Lee, JS | 1 |
| Lee, MS | 1 |
| Min, SY | 1 |
| Park, SK | 1 |
| Kang, HS | 1 |
| Maeng, YH | 1 |
| Kim, SY | 2 |
| Kook, YH | 1 |
| Kim, YR | 1 |
| Lee, KH | 1 |
5 other studies available for pyrazinoic acid and Tuberculosis, Multidrug-Resistant
| Article | Year |
|---|---|
Discovery and evaluation of new compounds targeting ribosomal protein S1 in antibiotic-resistant Mycobacterium Tuberculosis.
Topics: Acetamides; Anti-Bacterial Agents; Drug Discovery; Hypoxanthine; Microbial Sensitivity Tests; Molecu | 2020 |
Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis.
Topics: Aerosols; Animals; Antitubercular Agents; Bacterial Load; Disease Models, Animal; Drug Therapy, Comb | 2018 |
Population Pharmacokinetic Modelling of Pyrazinamide and Pyrazinoic Acid in Patients with Multi-Drug Resistant Tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Chromatography, Liquid; Female; Humans; Male; Middle Aged; | 2019 |
Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.
Topics: Administration, Inhalation; Aerosols; Animals; Antitubercular Agents; Esters; Guinea Pigs; Male; Mic | 2016 |
Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea.
Topics: Adult; Amidohydrolases; Antitubercular Agents; Bacterial Proteins; Base Sequence; DNA Mutational Ana | 2012 |